Lutris
Portfolio companies
Lutris Pharma is a clinical stage biopharmaceutical company established with a vision to improve anti cancer therapy effectiveness as well as the quality of life for patients who are being treated with EGFR (Epidermal Growth Factor Receptor) Inhibitors or with Radiation.
Dermal toxicity is the most prominent adverse reaction of EGFR Inhibitor and radiation therapy, often limiting anti cancer therapy compliance. Lutris Pharma aims to provide novel topical therapies that significantly mitigate these side effects and enable patients to adhere to effective anti cancer treatments with EGFR Inhibitors and radiation treatment. Since the indications relate to oncological patients, Lutris Pharma has received waivers from the FDA, and, as a result, the development pathway to approval is accelerated.
Lutris-Pharma is developing LUT014, a topical B-Raf Inhibitor, a proprietary, first-in-class, small molecule allowing administration of EGFR (Epidermal Growth Factor Receptor) Inhibitors to patients without interruptions caused by typical cutaneous side effects.
Leveraging the paradoxical effect of B-Raf Inhibitors, LUT014 decreases dermal toxicities associated with EGFR Inhibitors and radiation-induced dermatitis, thus reducing acneiform lesions associated with such therapy.